Abstract
Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Mini-Reviews in Medicinal Chemistry
Title:Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening
Volume: 13 Issue: 11
Author(s): M. V.V.V. Sekhar Reddy, Chakshusmathi Ghadiyaram, Sunil Kumar Panigrahi, Subramanya Hosahalli and Lakshmi Narasu Mangamoori
Affiliation:
Keywords: PTP1B, TCPTP, p-Nitro phenyl phosphate, Type II diabetes, Obesity.
Abstract: Even though protein tyrosine phosphatase has been identified as a validated therapeutic target over a decade for type II diabetes and obesity, developing a selective inhibitor to protein tyrosine phosphatase 1B (PTP1B) over other cellular PTPases has been a complicated task owing to the highly conserved and polar nature of the PTP1B catalytic site. Virtual screening study of in-house chemical depository resulted in the prioritization of few low molecular weight compounds as PTP1B inhibitors. The in-vitro pNPP assays were carried out on prioritized compounds in both PTP1B and T-cell protein tyrosine phosphatase (TCPTP). From this we identified four low molecular weight compounds as PTP1B inhibitors, of which the compound AU-2439 has shown 5 fold selectivity towards PTP1B over highly homologous TCPTP. In this short communication selectivity of AU-2439 is explained based on interaction with critical active site residues in both proteins using docking models.
Export Options
About this article
Cite this article as:
Reddy V.V.V. Sekhar M., Ghadiyaram Chakshusmathi, Panigrahi Kumar Sunil, Hosahalli Subramanya and Mangamoori Narasu Lakshmi, Diphenylether Derivative as Selective Inhibitor of Protein Tyrosine Phosphatase 1B (PTP1B) Over T-cell Protein Tyrosine Phosphatase (TCPTP) Identified through Virtual Screening, Mini-Reviews in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/1389557511313110006
DOI https://dx.doi.org/10.2174/1389557511313110006 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Network of WNT and Other Regulatory Signaling Cascades in Pluripotent Stem Cells and Cancer Stem Cells
Current Pharmaceutical Biotechnology Genomics and Pharmacogenomics in the Management of Breast Cancer
Current Pharmacogenomics and Personalized Medicine Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Therapeutic Potential of N-Acetylcysteine for Wound Healing, Acute Bronchiolitis, and Congenital Heart Defects
Current Drug Metabolism Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry Sodium-glucose Cotransporter 2 Inhibitors: The Pleiotropic Mechanisms of Actions
Cardiovascular & Hematological Disorders-Drug Targets Human Health Effects of Lactose Consumption as a Food and Drug Ingredient
Current Pharmaceutical Design The CRF Peptide Family in Appetite Regulation and Energy Balance
Current Medicinal Chemistry - Central Nervous System Agents Leukocyte- and Platelet-Rich Fibrin (L-PRF) for Long-Term Delivery of Growth Factor in Rotator Cuff Repair: Review, Preliminary Results and Future Directions
Current Pharmaceutical Biotechnology Maintenance of Gastrointestinal Glucose Homeostasis by the Gut-Brain Axis
Current Protein & Peptide Science Hepatocyte FRS2α is Essential for the Endocrine Fibroblast Growth Factor to Limit the Amplitude of Bile Acid Production Induced by Prandial Activity
Current Molecular Medicine Immune Response to Native Lipoproteins Induces Visceral Obesity and Aortic Wall Injury in Rats: The Role of Testosterone
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index to Volume 11
Protein & Peptide Letters Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Vasculopathy in Hyperthyroid Rats and Targets for Drug Effects
Vascular Disease Prevention (Discontinued) Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Chemokine Receptors as Specific Anti-Inflammatory Targets in Peripheral Nerves
Endocrine, Metabolic & Immune Disorders - Drug Targets Nicotine Effects on Human Affective Functions: A Systematic Review of the Literature on a Controversial Issue
CNS & Neurological Disorders - Drug Targets